Who are rosiglitazone maleate/metformin hydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): actoplus met.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rosiglitazone-maleate-metformin-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

rosiglitazone maleate/metformin hydrochloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

rosiglitazone maleate/metformin hydrochloride (rosiglitazone maleate/metformin hydrochloride) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione/Biguanide combination. Area: Diabetes.

marketed Thiazolidinedione/Biguanide combination PPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

rosiglitazone maleate/metformin hydrochloride (rosiglitazone maleate/metformin hydrochloride) — GlaxoSmithKline. This combination drug improves blood sugar control by increasing insulin sensitivity through a thiazolidinedione and reducing hepatic glucose production through a biguanide.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rosiglitazone maleate/metformin hydrochloride TARGET	rosiglitazone maleate/metformin hydrochloride	GlaxoSmithKline	marketed	Thiazolidinedione/Biguanide combination	PPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin)
actoplus met	actoplus met	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	Thiazolidinedione/Biguanide combination	PPAR-γ (pioglitazone component); Complex I of mitochondrial respiratory chain (metformin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione/Biguanide combination class)

GlaxoSmithKline · 1 drug in this class
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rosiglitazone maleate/metformin hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/rosiglitazone-maleate-metformin-hydrochloride. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab